Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agents.

Patients who received treatment after HMA/Ven failure had longer median OS compared to patients who did not receive additional therapy ( I n i = 17, 4.7 vs 1.7 months, HR = 0.29, 95% CI 0.13-0.62, I p i = 0.0017) (Figure 1(C)). The combination of Venetoclax (Ven) with hypomethylating agents (HMA/Ven) is the standard-of-care therapy for patients with newly diagnosed (ND) acute myeloid leukemia (AML) who are >= 75 years of age or have comorbidities that preclude the use of intensive chemotherapy (IC). A second study that assessed outcomes of patients after failure of salvage HMA/Ven found a somewhat longer median OS of 3.9 months; however, the median age of that cohort was younger, and a larger portion of those patients received treatment following HMA/Ven failure [[8]]. We report median OS in patients receiving additional therapy to be 4.7 months, which is comparable to that reported for R/R AML (4.3 months) and slightly longer than the median OS reported for patients receiving salvage therapy following frontline HMA/Ven failure (2.9 months) [[7]]. [Extracted from the article]